Oramed Pharmaceuticals Inc ORMP

Morningstar Rating
$4.33 +0.13 (3.10%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ORMP is trading at a LOCK|?S!>T^ premium.
Price
$4.34
Fair Value
LOCK|mYv>^vM
Uncertainty
LOCK|$q $B%hl
1-Star Price
LOCK|.>zX?w?V
5-Star Price
LOCK|!?$@%qK
Economic Moat
LOCK|?X#
Capital Allocation
—

Trading Information

Previous Close Price
$4.20
Day Range
$4.15–4.34
52-Week Range
$2.09–5.47
Bid/Ask
$4.16 / $4.50
Shares Outstanding
41.60M
Market Cap
$180.12M
Volume/Avg
193,501 / 192,525

Key Statistics

Price/Earnings (Normalized)
1.45
Price/Sales
—
Dividend Yield (Trailing)
5.77%
Dividend Yield (Forward)
5.77%
Dividend Payment Schedule
Jan
Total Yield
8.20%

Company Profile

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
13

Valuation

Metric
ORMP
Price/Earnings (Normalized)
1.45
Price/Book Value
0.56
Price/Sales
—
Price/Cash Flow
—
Price/Earnings
ORMP

Financial Strength

Metric
ORMP
Quick Ratio
4.77
Current Ratio
4.98
Interest Coverage
—
Quick Ratio
ORMP

Profitability

Metric
ORMP
Return on Assets (Normalized)
1.36%
Return on Equity (Normalized)
1.53%
Return on Invested Capital (Normalized)
−52.19%
Return on Assets
ORMP

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|$t#^ZZ&LOCK|@@C@$129B
Moderna Inc
MRNA
LOCK|VV<!pwVLOCK|w<$90B
Regeneron Pharmaceuticals Inc
REGN
LOCK|?SqS@$LOCK|#?Zt$77B
argenx SE ADR
ARGX
LOCK|TRTRy$LOCK|Gs$51B
BeOne Medicines Ltd ADR
ONC
LOCK|&JHt?hLOCK|#qQ$41B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|%^!R#F^LOCK|f$##$31B
Royalty Pharma PLC Class A
RPRX
LOCK|<@z>jvxLOCK|gVV!$25B
BioNTech SE ADR
BNTX
LOCK|vSb<dKLOCK|l?$24B
Incyte Corp
INCY
LOCK|?X#%@Z>LOCK|??N$23B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|M#Y>%%fLOCK|p^F$14B

Sponsor Center